Merus’ (MRUS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Merus (NASDAQ:MRUS) in a research report released on Friday, Benzinga reports. HC Wainwright currently has a $85.00 price objective on the biotechnology company’s stock.

Several other research firms also recently weighed in on MRUS. UBS Group began coverage on Merus in a research note on Thursday, October 24th. They set a “buy” rating and a $72.00 price target for the company. Canaccord Genuity Group raised shares of Merus to a “strong-buy” rating in a research report on Thursday, July 25th. Guggenheim raised their price objective on shares of Merus from $93.00 to $111.00 and gave the stock a “buy” rating in a report on Tuesday, October 1st. Needham & Company LLC lowered their target price on shares of Merus from $92.00 to $85.00 and set a “buy” rating on the stock in a report on Monday, August 5th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $67.00 price target on shares of Merus in a report on Thursday, July 25th. One equities research analyst has rated the stock with a sell rating, eleven have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $86.70.

Merus Stock Up 0.7 %

Merus stock opened at $50.30 on Friday. The company has a market capitalization of $3.43 billion, a P/E ratio of -12.73 and a beta of 1.12. The firm has a 50 day moving average price of $50.87 and a 200-day moving average price of $51.37. Merus has a twelve month low of $21.51 and a twelve month high of $61.61.

Merus (NASDAQ:MRUS) last announced its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.05). The firm had revenue of $7.33 million for the quarter, compared to the consensus estimate of $9.64 million. Merus had a negative net margin of 680.61% and a negative return on equity of 43.29%. Equities analysts expect that Merus will post -3.27 EPS for the current fiscal year.

Institutional Trading of Merus

Several institutional investors and hedge funds have recently modified their holdings of MRUS. Harbor Capital Advisors Inc. bought a new position in shares of Merus in the third quarter worth approximately $2,113,000. US Bancorp DE bought a new position in shares of Merus in the 3rd quarter worth $103,000. China Universal Asset Management Co. Ltd. raised its position in shares of Merus by 68.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,119 shares of the biotechnology company’s stock valued at $655,000 after buying an additional 5,336 shares in the last quarter. abrdn plc purchased a new stake in shares of Merus during the 3rd quarter valued at $4,357,000. Finally, Novo Holdings A S lifted its holdings in shares of Merus by 3.7% during the 3rd quarter. Novo Holdings A S now owns 700,000 shares of the biotechnology company’s stock worth $34,972,000 after acquiring an additional 25,000 shares during the last quarter. Hedge funds and other institutional investors own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.